Expertise in
1
conditions

Dr. Phoebe Rich

Dermatology
2565 Northwest Lovejoy Street, Suite 200, 
Portland, OR 
Accepting New Patients
Expertise in
1
conditions
2565 Northwest Lovejoy Street, Suite 200, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Phoebe Rich is a Dermatologist in Portland, Oregon. Dr. Rich is highly rated in 1 condition, according to our data. Her top areas of expertise are Yellow Nail Syndrome, Splinter Hemorrhages, Melanoma, and Warts. Dr. Rich is currently accepting new patients.

Her clinical research consists of co-authoring 76 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Specialist in OR
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

PacificSource
  • PPO
Regence
  • EPO
  • PPO

Locations

2565 Northwest Lovejoy Street, Suite 200, Portland, OR 97210

Additional Areas of Focus

Dr. Rich has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Yellow Nail Syndrome
Lichen Planus
Melanoma
Splinter Hemorrhages

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: April 26, 2024
Intervention Type: Drug, Biological
Study Drug: ASLAN004
Study Phase: Phase 2
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
Enrollment Status: Terminated
Publish Date: April 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: June 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

76 Total Publications

Richard K. Scher, MD.
Richard K. Scher, MD.
Journal: Journal of the American Academy of Dermatology
Published: September 11, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Alex G. Ortega-Loayza
Dermatology
Expertise in
19
conditions
Dr. Alex G. Ortega-Loayza
Dermatology

University Professional Services

3181 Sw Sam Jackson Park Rd, 
Portland, OR 
 (3.8 miles away)
503-494-8311
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alex Ortega-Loayza is a Dermatologist in Portland, Oregon. Dr. Ortega-Loayza is highly rated in 19 conditions, according to our data. His top areas of expertise are Pyoderma Gangrenosum, Pityriasis Rubra Pilaris, Calciphylaxis, and Psoriasis. Dr. Ortega-Loayza is currently accepting new patients.

Expertise in
12
conditions
Dr. Teri S. Greiling
Dermatology
Expertise in
12
conditions
Dr. Teri S. Greiling
Dermatology

University Professional Services

3181 Sw Sam Jackson Park Rd, 
Portland, OR 
 (3.8 miles away)
503-494-8311
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Teri Greiling is a Dermatologist in Portland, Oregon. Dr. Greiling is highly rated in 12 conditions, according to our data. Her top areas of expertise are Pityriasis Rubra Pilaris, Palmoplantar Keratoderma, Acrokeratoelastoidosis of Costa, and Cicatricial Pemphigoid. Dr. Greiling is currently accepting new patients.

Andrew Blauvelt
Expertise in
6
conditions
Dr. Andrew Blauvelt
Dermatology
Expertise in
6
conditions
Dr. Andrew Blauvelt
Dermatology
9495 Sw Locust Street, Suite A, 
Portland, OR 
 (7.1 miles away)
503-445-2200
Languages Spoken:
English
See accepted insurances

Andrew Blauvelt is a Dermatologist in Portland, Oregon. Dr. Blauvelt is highly rated in 6 conditions, according to our data. His top areas of expertise are Plaque Psoriasis, Psoriasis, Atopic Dermatitis, and Actinic Keratosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rich's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile